Efficacy and safety of Yimusake Tablets plus dapoxetine hydrochloride in the treatment of premature ejaculation / 中华男科学杂志

<p><b>Objective</b>To evaluate the effect and safety of Yimusake Tablets combined with dapoxetine hydrochloride and either of them used alone in the treatment of premature ejaculation (PE).</p><p><b>METHODS</b>We randomly assigned 180 PE patients to oral medication of Yimusake Tablets at 1.5 g per night (group A), dapoxetine hydrochloride at 30 mg at 1－3 hours before anticipated sexual activity (group B), the Yimusake Tablets plus dapoxetine hydrochloride simultaneously (group C), all for 8 weeks. After 4 and 8 weeks of medication, we recorded and compared the changes in the intravaginal ejaculation latency time (IELT), measures of the PE profile (PEP), and adverse events among the three groups of patients.</p><p><b>RESULTS</b>The treatment was accomplished and complete data obtained from 154 of the patients, 56 in group A, 52 in group B, and 46 in group C. After 4 and 8 weeks of medication, the mean IELT was dramatically prolonged in all the three groups as compared with the baseline (P<0.01), most significantly at 8 weeks in group C (［2.08±0.68］ min), followed by B (［1.76±0.52］ min) and A (［1.47±0.44］ min), with statistically significant differences among the three groups (P<0.01). The PEP measures were remarkably improved in group A at 8 weeks (P<0.05), and both in B and C at 4 and 8 weeks (P<0.05), most significantly at 8 weeks in group C (P<0.05), in which the patients scored 1.96±0.77 in perception of control over ejaculation, 2.62±0.98 in satisfaction with sexual intercourse, 3.04±0.62 in PE-related distress, and 3.57±0.80 in PE-induced difficult relationship with their partners, all markedly improved as compared with groups A and B (P<0.05). Adverse reactions were observed in 2 cases (3.6%) in group A, 6 cases (9.6%) in B, and 5 cases (10.9%) in C. No severe adverse events occurred in any of the patients during the study.</p><p><b>CONCLUSIONS</b>Combined medication of Yimusake Tablets and dapoxetine hydrochloride, with its advantages of effectiveness and safety, deserves to be recommended for the treatment of PE.</p>

Serum level changes of leptin and 5-hydroxytrytamine in patients with premature ejaculation before and after hydrochloride sertraline treatment / 中华全科医师杂志

A total of 71 patients with premature ejaculation (PE) received hydrochloride sertraline treatment for 8 weeks and their serum levels of leptin and 5-hydroxytrytamine (5-HT) were determined.Their ejaculation functions were assessed with intravaginal ejaculation latency time (IELT) and Chinese index of premature ejaculation (CIPE-5) value.The study was compared with 64 normal males as control.The baseline level of leptin in the trial group was obviously higher than the controls (P ＜ 0.05) while the level of 5-HT in the trial group far lower than the controls (P ＜ 0.05).At 8 weeks,the level of leptin dropped while the level of 5-HT rose in the trial group after treatment.Therefore a high serum level of leptin and a low serum level of 5-HT may become biological indicators for PE.

Association among leptin, 5-HT and premature ejaculation / 中华内分泌外科杂志

Objective To investigate the interrelationship between leptin and 5-hydroxy tryptamine (5-HT)and their significance in diagnosis of premature ejaculation(PE).Methods 71 cases with lifelong PE(the trial group)and 64 healthy males(the control group)were enrolled in this case-control study.Baseline recording of intravaginal ejaculation latency time(IELT) using a stop watch and Chinese Index of Premature Ejaculation-5 (CIPE-5) were done.The serum leptin and 5-HT levels were determined.Then the trial group were given sertraline hydrochloride for 8 weeks,while the control group were not given any medicine treatment in this period.Reassessment was done after 8 weeks.Results At the baseline,the leptin level in the trial group was obviously higher than the control group(P ＜ 0.05),while 5-HT level in the trial group was far lower than the control group(P ＜0.05).After 8 weeks,the leptin level of the trial group dropped and the difference had no statistical significance with that of the control group(P ＞0.05).5-HT level of the trial group rose to the level very close to that of the control group after the treatment.Conclusion The high level of serum leptin and low level of serum 5-HT were the meaningful biological indicators for PE,which can potentially be applied in PE diagnosis.

O ejaculador precoce por ele mesmo: um estudo piloto / The premature ejaculator by himself: a pilot study

Objetivo: Avaliar autopercepção de portadores de ejaculação precoce (EP), repercussão da disfunção sobre desempenho e satisfação sexual do casal e benefícios esperados com o tratamento.Métodos: Foi desenvolvido instrumento para acessar os objetivos do estudo. Ejaculadores precoces maiores de 18 anos foram recrutados, até completar amostra. Testes qui-quadrado e exato de Fisher verificaram associações entre EP e variáveis categóricas. Teste ?t de Student? comparou médias das variáveis contínuas. Valores de p£0,05 foram considerados estatisticamente significantes.Resultados: A amostra foi constituída por 32 indivíduos, 53,1% com EP ao longo da vida (EPL) e 46,9% EP adquirida (EPA), para os quais a EP se caracteriza por: falta de controle (100,0% dos EPL 70,6% dos EPA), breve tempo intravaginal (66,7% e 52,9%) e preocupação em satisfazer a parceira (33,3% e 64,7%). Impactam a vida do paciente: falta de controle da ejaculação para 100,0% dos EPL e 94,2% dos EPA (p=0,53) pouco tempo de penetração 93,4% e 88,2% (p=0,63) sofrimento pessoal 86,7% e 94,1% (p = 0,45) insatisfação pessoal com o intercurso 86,7% e 76,5% (p=0,76) insatisfação da parceira 86,7% e 88,2% (p=0,99). Medicamento associado a psicoterapia foi o tratamento preferencial para 40,0% (EPL) e 35,3% (EPA). Mais controle ejaculatório, tempo dentro da vagina e satisfação da parceira são as principais expectativas quanto ao tratamento.Conclusão: Para portadores de EPL, controle e tempo intravaginal são as características mais importantes de EP, enquanto aqueles com EPA valorizam controle e satisfação da parceira. Os dois grupos preferem tratamento combinado (medicação e psicoterapia), ainda que essa preferência não seja consenso.

New Approach and Treatment of Premature Ejaculation / 대한남성과학회지

Premature ejaculation (PE) is the most common form of male sexual dysfunction. Until very recently, scientific investigation of PE has been hampered by a lack of standardized definitions and objective, validated questionnaires. In recent years both the definition and the management of PE have changed from the traditional authority-based to a more evidence-based approach. In 2007, the International Society for Sexual Medicine (ISSM) established an ad hoc committee consisting of 21 internationally recognized experts, to establish a new definition of PE including intravaginal ejaculation latency time (IELT). As diagnostic tools, a brief self-administered questionnaire, the premature ejaculation diagnostic tool (PEDT), was developed and validated. Current accepted treatment options of PE include behavior therapy, topical desensitizing agents, selective serotonin reuptake inhibitors (SSRIs), clomipramine, tramadol, PDE-5 inhibitors. However, it should be noted that all of the medications currently used for treatment of PE were originally developed to treat other medical disorders such as depression or erectile dysfunction. Dapoxetine, a new SSRI, has a unique pharmacokinetic profile, with a short time to maximum serum concentration, and rapid elimination. By 24 hours, plasma concentrations are less than 5% of peak values. These attributes make Dapoxetine suitable for on-demand therapy of PE. This paper reviewed new diagnostic tools and treatment options for PE.